Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Athersys logo — Committed to developing therapies to extend and enhance the...

Athersys

Committed to developing therapies to extend and enhance the quality of life.

Founded 1995 United States Cleveland, United States 37 employees Post-IPO Equity Total: $208.90M Biopharma, Biotechnology +2

General Information

Company Name Athersys
Founded Year 1995
Location United States Cleveland, United States
Founders / Decision Makers
Team member
Employees 37
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Athersys. To contact Athersys, visit athersys.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Athersys compare?

A PDF of Athersys and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Athersys soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Athersys

Athersys is a biopharmaceutical company committed to developing therapies to extend and enhance the quality of life. Established in 1995 and headquartered in the United States, Athersys focuses on the discovery and development of innovative medicines to treat significant and life-threatening diseases. The company's pipeline of potential best-in-class therapeutics includes stem cell therapy and pharmaceuticals, employing proprietary technologies. Recently, Athersys secured a $3.70M Post-IPO Equity investment on 18 April 2023, showcasing ongoing support for its advancements in the field of biopharma, biotechnology, healthcare, and life sciences. With a promising future, Athersys stands as a compelling prospect for potential investors in the healthcare sector.

Business keywords: biopharmaceutical, therapeutics, clinical stage, drug development, regenerative medicine, stem cell therapy, pharmaceuticals, innovation, disease indications, clinical trials, proprietary technologies, life-threatening diseases, quality of life, multi-disease indications

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $3.70M -
18 Apr 2023
Post IPO Equity $5.50M -
09 Nov 2022
Post IPO Equity $12.00M -
15 Aug 2022
Post IPO Equity $57.60M -
20 Apr 2020
Post IPO Equity $23.00M -
02 Feb 2017
Post IPO Equity $9.00M 3
First Analysis William Blair
First Analysis, William Blair +1
23 Mar 2012
Post IPO Equity $20.00M 1
Aspire Capital Partners, LLC
Aspire Capital Partners, LLC
14 Nov 2011
Post IPO Equity $13.10M 2
First Analysis William Blair
First Analysis, William Blair
28 Jan 2011
Venture Round $65.00M 7
MPM Capital RA Capital Management OrbiMed
MPM Capital, RA Capital Management +5
12 Jun 2007

Athersys Alternatives & Competitors

View All Alternatives
Athersys vs
Juventas Therapeutics
Juventas Therapeutics

Pioneering regenerative therapies for life-threatening diseases with a robust clinical pipeline and...

Series B
Biotechnology, Health Care
Compare Athersys vs Juventas Therapeutics
Athersys vs
Stemedica Cell Technologies, Inc
Stemedica Cell Technologies, Inc United States

Developing Breakthrough Progenitor Cell and Protein Therapeutics

Series B
16 employees
Biotechnology, Health Care
Compare Athersys vs Stemedica Cell Technologies, Inc
Athersys vs
BlueRock Therapeutics
BlueRock Therapeutics United States

Striving to transform the treatment of disease by harnessing the power of cell therapy

Acquired
478 employees
Biopharma, Biotechnology
Compare Athersys vs BlueRock Therapeutics
Also compare with: Athersys vs Plexxikon Inc. Plexxikon Inc. View all alternatives

FAQ About Athersys

Committed to developing therapies to extend and enhance the quality of life.
Athersys was founded in 1995.
Athersys is headquartered in Cleveland, United States.
Athersys operates in Biopharma, Biotechnology, Health Care and Life Sciences. Its work centres on biopharmaceutical, therapeutics, clinical stage and drug development.
Athersys has approximately 37 employees.
Athersys has completed 9 funding rounds, raising a total of $208.90M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Athersys include Juventas Therapeutics, Stemedica Cell Technologies, Inc, BlueRock Therapeutics, Benitec Biopharma Inc., Angiocrine Bioscience, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Athersys and Juventas Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Athersys, https://bouncewatch.com/company/athersys, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes